| INTRODUCTION
Inflammatory bowel disease (IBD) is a lifelong disease with unknown aetiology and pathogenesis. 1, 2 Its clinical course is characterised by periods of remission interrupted by periods of active inflammation, which causes symptoms. IBD mainly affects young adults, causing significant morbidity and impacting quality of life. Furthermore, as IBD often presents early in life, it can compromise education, career development and family planning. Despite significant advances in medical therapy, IBD remains a progressive and disabling disease that over time results in bowel damage and significant disability that profoundly impacts patients' lives. During the last decades, diseaserelated outcomes (eg disease activity, disease-related hospitalisation and disease-related surgery) have been used as primary outcomes during clinical trials. However, the United States food and drug administration (FDA) is beginning to shift from disease-related outcomes as its primary endpoints towards accepting patient-reported outcomes and clinician-reported outcomes. 3, 4 Much effort has been put into investigating quality of life, while less work has been carried out in exploring disability, in IBD patients. 5 Quality of life is a subjective measure of the disease burden and is therefore dependent on the attitude of the patient, whereas disability is an objective measure of the impact on activity and is independent of the attitude of the patient. The World Health Organization (WHO) defines disability as "any restriction or lack (resulting from an impairment) of ability to perform an activity in the manner or within the range considered normal for a human being." 6 Thus, the ultimate treatment goal should be the reduction of long-term disability.
In 2012, the IBD disability index (IBD-DI) was developed according to the FDA's guidelines and the International Classification of Functioning, Disability and Health, from the WHO. An international cooperation, including both patients and experts, led to the selection of 19 core sets, comprised of 28 questions. 7 Recently, several studies have investigated disability using the IBD-DI and have been validating the questionnaire according to the consensus-based standards for the selection of health measurement instruments (COSMIN), a manual and checklist for health-related patient-reported outcomes. 8 We conducted this meta-analysis and systematic review to assess disability severity and its associated factors. Secondly, we wanted to examine the validity of the questionnaire, as well as its strengths and limitations.
| ME TH ODS
This study was performed according to the PRISMA recommendations 9 and MOOSE guidelines. 10 The review protocol was published at PROSPERO (PROSPERO 2017:CRD42017056383)
| Searches
A literature review of the computerised databases MEDLINE, using
PubMed, EMBASE and Cochrane, was conducted between 9 and 23 January 2017. To increase sensitivity, searches using both free text and MESH terms were used. MESH terms included "Inflammatory bowel disease" and "disability evaluation," while free-text search terms included "inflammatory bowel disease disability index." Additionally, we included published conference abstracts and used manual searches for all references among relevant articles and reviews. 
| Eligible studies
We included only observational and cross-sectional studies published in English, investigating disability levels among patients with either Crohn's disease (CD) or ulcerative colitis (UC), above the age of 16, and using the IBD-DI with a score range of either À80 to 22 or 0 to 100. The scale from À80 to 22 was developed by Leong et al as there was no official scoring system developed at that time for the IBD-DI. A score of À80 was considered the most severe disability, while a score of 22 was no disability. Gower-Rousseau et al developed the scale from 0 to 100 subsequently in cooperation with the developers of the IBD-DI, where a score of 0 was considered as no disability and a score of 100 was the most severe disability. No publication date or publication status criteria were imposed. No criteria for method were imposed when assessing studies for validation.
| Study selection
Two independent, blinded authors performed the literature search (BL: medical student, MP: MD). Disagreements were solved by consensus using a third author (JB: MD, PhD). The search results were first screened by title and abstract and subsequently excluded if found not to be relevant; the remaining results were then screened by full text. The process is summarised in Figure 1 . Full texts that were excluded are listed with the reason for their exclusion in 
| Data extraction
Data were extracted independently by 2 blinded investigators (BL, MP). Any discrepancies were resolved by consensus involving a third author (JB). An attempt to contact the corresponding author by email was made when the data were not available.
A data extraction protocol was developed based on the Cochrane Consumers and Communication Review Group's data and result template and refined accordingly. The following information was extracted from each study: (1) publication year and study design, (2) validity (including internal consistency, intra-rater and inter-rater reliability, the construct and structural validity, responsiveness and interpretability) and (3) the disability level (Mean and SD) LO ET AL. Figure 1 . Eight studies were included in the systematic review as well as in the meta-analysis.
| Study characteristics
Of the 9 studies included, 6 were published articles, while 3 were only to be found as published abstracts. All authors were contacted for unpublished results. Authors of 7 studies provided additional data [13] [14] [15] [16] [17] [18] [19] (Table S1 ). A summary of the studies included can be found in Table 1 . Five studies used the scale from 0 to 100 and 4 studies used the scale from À80 to 22. The 9 studies included a total of 3167 patients. All studies were cross-sectional studies. The studies were conducted mainly in Europe and Australia. For measuring disease activity, the Harvey-Bradshaw index 14, 15, 19, 20 and the Crohn's Disease activity index 16, 18 were used for CD patients, and the Partial T A B L E 1 Characteristics of included studies using the inflammatory bowel disease disability index and assessment of the risk of bias Mayo score, 14, [18] [19] [20] the Truelove and Witts severity index, 16 and the Simple Clinical Colitis Activity index 15 were used for UC patients.
Only Chan et al 17 did not specify how disease activity was measured.
| Risk of bias
The risk of bias is summarised in Table 1 . It was not possible for any of the studies to receive 3 stars for outcome because the disability index is self-reported. The paper by van der List et al received 1 star in comparability, as it could only be included in the comparison of CD with UC.
| Validation
The validation of the IBD-DI performed for the studies is summarised in Table 2 . Internal consistency was measured using Cronbach's alpha. Intra-rater reliability was measured by intra-class correlation or by retesting for significant differences. Inter-rater reliability was measured by intra-class correlation. disease activity using Wilcoxon signed-rank test, effect size and responsiveness coefficient, or by a correlation coefficient lower than À0.4 when comparing IBD-DI score and global perceived effect score and obtaining the standardised response mean and effect size.
Interpretability was assessed by floor and ceiling effects and minimal important change in the IBD-DI score and changes in the score across the entire sample and relevant subgroups.
The IBD-DI scored "good" for internal consistency, "fair" to "excellent" for intra-rater reliability and "excellent" for inter-rater reliability.
Its construct validity scored "moderately strong" to "very strong,"
while structural validity was found in 2 studies to be unidimensional 14, 20 and in 1 18 to be multidimensional. IBD-DI had excellent responsiveness, while its interpretability was useful on a group level (more than 1 person) but not on an individual level. Intra-rater reliability was measured differently between studies. Leong et al 18 found no significant difference between the 2 tests (and interpreted as "excellent" the intra-rater reliability), but did not assess the reliability level.
Two studies assessed the intra-rater reliability by intra-class correlation; one found it to be "fair" 14 and the other as "excellent"
20
( Table S2 ).
| Disability score in UC and CD patients
Nine studies, including a total of 3167 patients, assessed disability levels; of these, 8 compared patients with CD and UC; 7 compared the disability levels between patients with active disease and those in remission; 6 assessed the disability levels of patients who had undergone surgical interventions and patients who had received biological treatment; and 5 of the studies assessed the disability levels of patients who had received biological treatment or who had received corticosteroids.
The number of patients in each group, the mean and standard deviation, and the difference among them in terms of disability, is summarised in Figures 2-5 . Regarding disability in CD and UC, no significant difference was found in the random model (SMD 
| Associated factors
In total, 5 studies with a combined 2608 patients investigated factors associated with increased disability (Table 2) . In summary, all of these studies found disease activity to be an associated factor, and those studies that investigated patients' employment status found unemployment to be an associated factor too. Three studies found female gender to be associated with disability, while 2 studies did not.
None of the studies that assessed surgery and smoking found any association with disability. Phenotype, extraintestinal manifestations, medical treatment, and age or age at diagnosis were found in most studies to be non-associating factors. However, due to heterogeneity between the studies, these results should be interpreted with caution.
However, we did not find any significant differences in disability between patients who underwent surgery and those who received biological treatment; this is in contrast to a recent study indicating that receiving biological treatment predicts increased disability. 21 Regulatory institutions are shifting their emphasis from diseaserelated outcomes towards patient-reported outcomes. The correlation between patient-reported outcomes is generally high but associated factors should be compared and evaluated in future studies. 14, 15, 18, 20, 22, 23 Several studies have investigated different kinds of patient-reported outcomes (eg IBDQ, SF36 and FACIT-F) and factors associated with worse outcomes (eg female gender, smoking and disease activity). 15, [24] [25] [26] Thus, factors found in this review to be associated with high disability are comparable, although medical treatment (eg biological therapy) and smoking
were not associated with worse disability. Reasons for this discrepancy might be found in the construction of the questionnaire;
the IBD-DI, unlike the other questionnaires described, was constructed according to the FDA's guidelines for patient-reported outcomes. 3 Disability limits access to education and employment and leads to economic and social exclusion, 27 and so reduction in disability should be a long-term goal. An international consensus agreed that patient-reported outcomes must be taken into account as a treatment target. 28 It is therefore important to map the factors associated with worsening of patient-reported outcomes in order to improve treatment and the perception of improved health among patients. In one recent study, medication compliance was associated with lower disability, suggesting that efforts ought to be made in this regard to improve patients' disability. 29 In this meta-analysis, and in line with recent studies on quality of life in a variety of treatment groups, [30] [31] [32] [33] [34] we conclude that patients with active disease, who are receiving corticosteroid treatment, have a worse disability level than those receiving biological treatment.
| Validation of IBD-DI
Currently only 5 studies have validated the IBD-DI. Nonetheless, the IBD-DI shows "good" internal consistency, "excellent" inter-rater reliability and "moderately strong" to "very strong" construct validity.
The discrepancy in intra-rater reliability could be explained by the design of the 2 studies 14, 20 (number of patients, language, days to retest). In Gower-Rousseau et al's study, the median time to retest was 3.8 weeks, which could have affected the intra-rater reliability as patients could have improved or deteriorated between assessments. The inter-rater reliability was assessed by the 2 investigators on the same day. This approach explains the overall better interrater reliability over the intra-rater reliability. 
| Strengths and weaknesses
This systematic review and meta-analysis was published in PROS-PERO in order to avoid reporting bias. The systematic review ensures no selection bias of the literature and we contacted the included authors to ensure we were in possession of the complete data. However, some limitations of this systematic review and metaanalysis need to be acknowledged. First, the number of studies available was small, and of these only cross-sectional studies were available, all of which can lead to selection bias. The studies also originated mainly from Europe to Australia. Future population-based inception studies are needed to avoid selection bias and should be carried out in the north and south Americas, and in Asia and Africa.
Second, in 2 of the 4 meta-analyses, the heterogeneity was more than moderate, thus reducing our ability to interpret the results and draw conclusions with much certainty. However, we believe that patients with active disease experience more disability than do those in remission. We must also underline that the differences in phenotype were only found in the fixed model. If one excludes van der
Have et al, no significant difference was found between the fixedand random-effect models, or between the subgroups. Furthermore, the difference between subgroups in the analysis comparing active disease and remission might be explained by the definition of active disease and use of different disease activity indices. Nonetheless, the results show that patients with active disease experience a higher level of disability. Third, we did not have access to complete treatment data; some patients could potentially have received both steroids and biological therapy and thus appear in both groups when comparing biological treatment with corticosteroids, for instance.
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This might be why no difference in disability rates was found between patients receiving biological treatment and surgical intervention, as patients appeared in both groups, thereby pulling the analysis towards the middle. At the same time, this underlines the finding that biological treatment induces less disability as compared to corticosteroid treatment. Fourth, the consequences of using different scales have yet to be established. However, in our meta-analysis, when reviewing the forest plots, there are no obvious differences in the distribution of disability apart from those described above.
| CONCLUSIONS
In conclusion, this systematic review and meta-analysis found a significant association between disease activity, as well as treatment received, and disability. The IBD-DI is a reliable and valid questionnaire but further studies are needed to measure its responsiveness and interpretability. A consensus on which scale to use for measuring disability is necessary, and future studies are needed in order to fully map the disability levels between treatment groups and phenotypes. 11. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. 
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